Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Location
1601 Trapelo Road, Suite 286, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 709 % -38.1%
Debt-to-equity -232 % +13.3%
Return On Equity -41.4 % -140%
Return On Assets 31.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.99M shares 0%
Common Stock, Shares, Outstanding 6.99M shares 0%
Entity Public Float 12.9M USD -65%
Common Stock, Value, Issued 699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.57M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.57M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.53M USD -59.7%
General and Administrative Expense 9.63M USD -3.83%
Operating Income (Loss) -16.2M USD +38.3%
Net Income (Loss) Attributable to Parent 11.2M USD +60.4%
Earnings Per Share, Basic 1 USD/shares +60.6%
Earnings Per Share, Diluted 1 USD/shares +60.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.2M USD -50.6%
Assets, Current 15.5M USD -50.5%
Property, Plant and Equipment, Net 2.72K USD -66.7%
Goodwill 14.9M USD 0%
Assets 30.4M USD -34.3%
Accounts Payable, Current 897K USD +8.26%
Liabilities, Current 2.53M USD -39.8%
Liabilities 62.5M USD -31.1%
Retained Earnings (Accumulated Deficit) -402M USD +2.72%
Stockholders' Equity Attributable to Parent -32.1M USD +27.8%
Liabilities and Equity 30.4M USD -34.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.07M USD +33.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 6.99M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.07M USD +33.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.3M USD -50.5%
Deferred Tax Assets, Valuation Allowance 96.1M USD -0.84%
Deferred Tax Assets, Gross 96.1M USD -0.84%
Deferred Tax Assets, Operating Loss Carryforwards 42.9M USD +24.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 1.15M USD -34.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%